House Bill 1034
116th Congress(2019-2020)
Phair Pricing Act of 2019
Introduced
Introduced in House on Feb 7, 2019
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1034
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Doug Collins
grade
Georgia
Alabama
Alabama
Alabama
Alabama
Arkansas
Arkansas
Arkansas
Arkansas
California
Delaware
Florida
Florida
Florida
Florida
Georgia
Georgia
Georgia
Georgia
Georgia
Georgia
Georgia
Iowa
Iowa
Iowa
Iowa
Kansas
Kansas
Kentucky
Louisiana
Louisiana
Louisiana
Louisiana
Maine
Maryland
Maryland
Mississippi
Mississippi
Missouri
Missouri
New Jersey
New York
New York
New York
New York
North Carolina
North Carolina
North Carolina
North Dakota
Ohio
Oklahoma
Oklahoma
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
South Carolina
Tennessee
Tennessee
Tennessee
Tennessee
Tennessee
Texas
Texas
Texas
Texas
Texas
Texas
Utah
Vermont
Virginia
Virginia
Virginia
Washington
Washington
West Virginia
Wisconsin
Wisconsin
No House votes have been held for this bill.
Summary
Phair Pricing Act of 2019
This bill requires that certain negotiated prices for covered drugs under the Medicare prescription drug benefit be disclosed at the point-of-sale.
Specifically, negotiated prices offered under a prescription drug plan (PDP) must be disclosed at the point-of-sale; the disclosed price must include specified adjustments, payments, and fees that are negotiated with the pharmacy (e.g., dispensing fees) by the PDP sponsor or pharmacy benefit manager.
Additionally, the Centers for Medicare & Medicaid Services must establish certain quality measures for PDP sponsors to use when determining incentive payments and adjustments (e.g., performance payments) to pharmacies.
February 7, 2019
02/07/2019
Referred to the Subcommittee on Health.
02/07/2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
02/07/2019
Introduced in House
Public Record
Record Updated
Nov 1, 2022 3:47:47 PM